STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
Source ↗
👁 0
💬 0
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals, as the outlook wavers for its two ATTR-CM drugs because of a competing drug’s surprising failure in the same heart disease.
Cardiologists and investors attending the ESC me
The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals, as the outlook wavers for its two ATTR-CM drugs because of a competing drug’s surprising failure in the same heart disease.
Cardiologists and investors attending the ESC me
Comments (0)